Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Fluorouracil 616Oxaliplatin 579Gemcitabine 492Capecitabine 445Leucovorin 427Irinotecan 390Bevacizumab 330Cisplatin 320Radiotherapy 245Cetuximab 215Sorafenib 167pembrolizumab 150Docetaxel 150Paclitaxel 140Nivolumab 128Albumin-Bound Paclitaxel 108130-nm albumin-bound paclitaxel 108Folfox protocol 101Panitumumab 95Erlotinib Hydrochloride 95Surgical Procedures, Operative 86regorafenib 84S 1 (combination) 81Drug Therapy 80Radiation 69Carboplatin 65Neoadjuvant Therapy 64Colonoscopy 64Radiosurgery 62Surveys and Questionnaires 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × LGK974 × Gastrointestinal × Clear all
NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02278133 2017-10-09

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Array BioPharma

Phase 1/2 Completed
20 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡